HER2‐Targeted Antibody‐Drug Conjugate Toxicities in Breast Cancer

ABSTRACT Background HER2‐targeted antibody‐drug conjugates (ADCs) have dramatically advanced breast cancer outcomes. Two HER2‐targeted ADCs, trastuzumab deruxtecan and trastuzumab emtansine, are currently approved for use in breast cancer, with > 60 other candidates under ongoing investigation. Meth...

Full description

Bibliographic Details

Main Authors:	Seohyuk Lee, Adriana M. Kahn, Mariya Rozenblit, Mridula A. George, Cristina Naranjo Ortiz, Maryam B. Lustberg
Format:	Artigo
Language:	Inglês
Published:	Wiley 2025-12-01
Series:	Cancer Medicine
Subjects:	antibody‐drug conjugate breast cancer HER2 toxicity
Online Access:	https://doi.org/10.1002/cam4.71415
Tags:	Add Tag No Tags, Be the first to tag this record!